| Filed On | Filing |
|---|---|
| 12 Nov 2026 | Form 4 |
| 10 Nov 2026 | 144 |
| 09 Nov 2026 |
8-K: Other Events
As previously reported, on November 5, 2026, Precision BioSciences, Inc. (the “Company”) entered into an underwriting agreement relating to the issuance and sale by the Company of 10,235,077 shares of its common stock, $0.000005 par valu... |
| 06 Nov 2026 | 144 |
| 06 Nov 2026 |
8-K: Other Events
Exhibit 1.1 Precision BioSciences, Inc. 10,235,077 Shares of Common Stock, par value $0.000005 per share and Pre-Funded Warrants to Purchase up to 5,893,964 Shares of Common Stock Underwriting Agreement November 5, 2026 TD Securities (US... |
| 06 Nov 2026 | 424B5 |
| 05 Nov 2026 | 144 |
| 05 Nov 2026 | FWP |
| 05 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
AASLD 2026 Investor Update: Direct cccDNA Elimination Leads to an Era of Potential Chronic Hepatitis B Viral Cure Confidential |
| 03 Nov 2026 | SCHEDULE 13G/A |
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
- PBGENE-HBV late-breaking oral presentation for ELIMINATE-B trial at AASLD's The Liver Meeting® 2026 on November 8; data abstract scheduled for release November 5 - |
| 03 Nov 2026 | 10-Q |
| 27 Oct 2026 | SCHEDULE 13G |
| 30 Sep 2026 |
Form 4: Frankel Stanley, Director
Bought 1,000 shares ($6K) |
| 29 Sep 2026 |
Form 4: Germano Geno J, Director
Bought 2,609 shares ($16.4K) |
| 29 Sep 2026 |
Form 4: Brown Melinda, Director
Bought 1,135 shares ($7.12K) |
| 24 Aug 2026 | SCHEDULE 13G/A |
| 24 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
-First patient dosed with PBGENE-DMD, the first clinical gene-editing program for DMD – |
| 07 Aug 2026 | S-8 |
| 06 Aug 2026 | 10-Q |
Loading...